Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298063 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1298064 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2961543 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2957502 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2851892 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1297864 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1297660 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2961541 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL6160001 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2518872 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2025-06-19 | — | — | US | disclosed |
| CN-119775168-A | Synthesis method of chiral cis (cis) -2-amino-1-cyclopropylcarboxylic acid | 杭州澳赛诺生物科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4499643-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1st Biotherapeutics, Inc. (KR) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-119212997-A | Indazoles as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) and methods of use thereof | 第一生物治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024182569-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-09-06 | — | — | WO | disclosed |
| EP-1227084-B1 | DRUG DISCHARGE PUMP INHIBITORS | TRINE PHARMACEUTICALS INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6949662-B2 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-0919553-B1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20020183523-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD | 2002-12-05 | — | — | US | disclosed |
| US-6462040-B1 | MICROBIOCIDES; BACTERIOCIDES; ANTIPROTOZOA AGENTS; QUINOLONE ANTIBIOTICS; SIDE EFFECT REDUCTION; ANTIBIOTIC-RESISTANT BACTERIA INCLUDING STAPHYLOCCOCUS; VETERINARY MEDICINE | DAIICHO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-1227084-A1 | DRUG DISCHARGE PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6391889-B2 | POTENT ANTIMICROBIAL ACTIVITY ON BROAD RANGE OF MICROORGANISMS, E.G., STAPHYLOCOCCUS, GRAMPOSITIVE BACTERIA AND QUINOLONE ANTIBIOTIC RESISTANCE; SIDE EFFECT REDUCTION; NONTOXIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-05-02 | — | — | US | disclosed |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-0919553-A1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | CYP3A4 472/4885CYP1A2 825/4885CYP2D6 144/4885 |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | PHOSPHO1, CCR2, ECH1 | CYP3A4 1440/4885CYP1A2 1677/4885CYP2D6 1571/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | CYP3A4 4634/4885CYP1A2 2495/4885CYP2D6 3676/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | CYP3A4 3243/4885CYP1A2 4586/4885CYP2D6 3824/4885 |
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | IP6K1, HIPK1, IP6K3 | CYP3A4 2056/4885CYP1A2 2137/4885CYP2D6 3103/4885 |
| US-20020183523-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | CYP3A4 472/4885CYP1A2 825/4885CYP2D6 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.